Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 4/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19345127 | 0.78 | — | — | |
| SCHEMBL22311655 | 0.76 | MGLL (0.36) | LMNASMN1; SMN2MGLLPTGS1PTGS2 | |
| SCHEMBL22147203 | 0.75 | MGLL (0.37) | LMNASMN1; SMN2MGLLPTGS1PTGS2 | |
| SCHEMBL3482625 | 0.73 | MGLL (0.50) | LMNASMN1; SMN2MGLLPTGS1PTGS2 | |
| SCHEMBL3482787 | 0.71 | MGLL (0.47) | LMNASMN1; SMN2MGLLPTGS1PTGS2 | |
| SCHEMBL1535492 | 0.69 | MGLL (0.44) | LMNASMN1; SMN2MGLLPTGS1PTGS2 | |
| SCHEMBL18715951 | 0.69 | REN (0.32) | LMNASMN1; SMN2MGLLPTGS1PTGS2 | |
| SCHEMBL18639285 | 0.69 | REN (0.32) | LMNASMN1; SMN2MGLLPTGS1PTGS2 | |
| SCHEMBL17924933 | 0.68 | MGLL (0.32) | LMNAMGLLALDH1A1MAPT | |
| SCHEMBL18384190 | 0.67 | PTGS1 (0.40) | LMNASMN1; SMN2MGLLPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10328158-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-06-25 | — | — | US | disclosed |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | CD47, CD274, TP53 | LMNA 4452/4885SMN1; SMN2 1311/4885MGLL 2149/4885 |
| US-10328158-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | LMNA 4452/4885SMN1; SMN2 1311/4885MGLL 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.